InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc.verified

INM

Price:

$0.243

Market Cap:

$3.24M

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosyn...[Read more]

Industry

Biotechnology

IPO Date

2014-05-05

Stock Exchange

NASDAQ

Ticker

INM

The Enterprise Value as of November 2024 (TTM) for InMed Pharmaceuticals Inc. (INM) is 641.54M

According to InMed Pharmaceuticals Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 641.54M. This represents a change of 308.58% compared to the average of 157.02M of the last 4 quarters.

InMed Pharmaceuticals Inc. (INM) Historical Enterprise Value (quarterly & annually)

How has INM Enterprise Value performed in the past?

The mean historical Enterprise Value of InMed Pharmaceuticals Inc. over the last ten years is 86.58M. The current 641.54M Enterprise Value has changed 73.99% with respect to the historical average. Over the past ten years (40 quarters), INM's Enterprise Value was at its highest in in the June 2024 quarter at 640.22M. The Enterprise Value was at its lowest in in the June 2018 quarter at -18350271.00.

Quarterly (TTM)
Annual

Average

86.58M

Median

19.45M

Minimum

-6251089.43

Maximum

640.20M

InMed Pharmaceuticals Inc. (INM) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of InMed Pharmaceuticals Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 306.98%

Maximum Annual Enterprise Value = 640.20M

Minimum Annual Increase = -10341.45%

Minimum Annual Enterprise Value = -6251089.43

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2024640.20M-10341.45%
2023-6251089.43-618.45%
20221.21M-91.61%
202114.37M-62.67%
202038.50M-20.54%
201948.45M-45.70%
201889.23M263.82%
201724.53M306.98%
20166.03M-37.19%
20159.59M-54.14%

InMed Pharmaceuticals Inc. (INM) Average Enterprise Value

How has INM Enterprise Value performed in the past?

The current Enterprise Value of InMed Pharmaceuticals Inc. (INM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

211.72M

5-year avg

137.61M

10-year avg

86.58M

InMed Pharmaceuticals Inc. (INM) Enterprise Value vs. Peers

How is INM’s Enterprise Value compared to its peers?

InMed Pharmaceuticals Inc.’s Enterprise Value is greater than Quoin Pharmaceuticals, Ltd. (3.24M), greater than Allarity Therapeutics, Inc. (-15916163.00), greater than Kiromic BioPharma, Inc. (10.92M), greater than Virax Biolabs Group Limited (5.49M), greater than Biodexa Pharmaceuticals Plc (-2508868.64), greater than SeaStar Medical Holding Corporation (14.26M), greater than Virios Therapeutics, Inc. (-2813681.00), greater than ZyVersa Therapeutics, Inc. (1.84M), greater than Sonnet BioTherapeutics Holdings, Inc. (-448232.00), greater than Revelation Biosciences, Inc. (-8886223.00), greater than Palisade Bio, Inc. (-7153934.00), greater than Bright Minds Biosciences Inc. (307.78M), greater than Tonix Pharmaceuticals Holding Corp. (24.56M), greater than Immix Biopharma, Inc. (20.49M), greater than Phio Pharmaceuticals Corp. (-1935086.00), greater than 180 Life Sciences Corp. (2.81M), greater than Navidea Biopharmaceuticals, Inc. (-2504975.00), greater than Sigilon Therapeutics, Inc. (43.98M), greater than NovaBay Pharmaceuticals, Inc. (4.95M), greater than GeoVax Labs, Inc. (13.84M),

Build a custom stock screener for InMed Pharmaceuticals Inc. (INM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like InMed Pharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

InMed Pharmaceuticals Inc. (INM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like InMed Pharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is InMed Pharmaceuticals Inc.'s Enterprise Value?

What is the highest Enterprise Value for InMed Pharmaceuticals Inc. (INM)?

What is the 3-year average Enterprise Value for InMed Pharmaceuticals Inc. (INM)?

What is the 5-year average Enterprise Value for InMed Pharmaceuticals Inc. (INM)?

How does the current Enterprise Value for InMed Pharmaceuticals Inc. (INM) compare to its historical average?